21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase Download PDF Post navigationPreviousPrevious post:AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037NextNext post:Success of the capital increase by private placement for an amount of 15 million eurosRelated PostsAB Science webcast – Masitinib in Sickle Cell Disease30 November 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023Revenues for the first half of 2023 and update on AB Science’s activities29 September 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease28 November 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”27 November 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS18 September 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)26 June 2023
